Stereotaxis rises after FDA clears new heart-procedure platform
Shares of medical robotics firm Stereotaxis STXS.A rise 9% to $2 premarket
Co says it has won FDA clearance for its Synchrony system to modernize cardiac catheterization labs, which are rooms where doctors perform heart procedures using thin tubes inserted into blood vessels
Co says Synchrony combines video and controls from multiple devices on one high-definition screen, aiming to simplify workflow, improve efficiency and enable secure remote collaboration
Brokerage TD Cowen says STXS has generated strong initial demand for the technology, which it projects will deliver over $3 million in revenue in 2026 as multiple US hospitals standardize their EP labs with it
Brokerage adds STXS plans to complete the development of the first AI features that will be incorporated into Synchrony this year
Brokerage reiterates Stereotaxis at ‘Buy’, keeps PT at $5
As of last close, shares down ~19% YTD
